Neurocrine Biosciences Tender Offer for Soleno Therapeutics Clears HSR Regulatory Hurdle
SLNO sits 79% above its 52-week low of $29.43 on light trading volume (0.4× avg).
Summary
Neurocrine Biosciences announced that the waiting period under the HSR Act for its tender offer to acquire Soleno Therapeutics has expired, satisfying a key regulatory condition for the acquisition.
Key Events · M&A and Partnerships · SLNO
-
HSR Act Waiting Period Expired
The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) applicable to the tender offer expired on April 27, 2026. This satisfies a key regulatory condition for the acquisition.
-
Tender Offer Progress
This amendment relates to the ongoing tender offer by Sigma Merger Sub, Inc., a subsidiary of Neurocrine Biosciences, to acquire all outstanding shares of Soleno Therapeutics for $53.00 per share in cash. The offer remains subject to other conditions.
Analysis · SLNO · Life Sciences
This amendment signals a significant step forward in the acquisition of Soleno Therapeutics by Neurocrine Biosciences. The expiration of the HSR Act waiting period satisfies a critical regulatory condition, substantially de-risking the tender offer. This increases the certainty that the acquisition will close as planned, providing clarity for Soleno shareholders regarding the $53.00 per share cash offer. Investors should monitor the remaining offer conditions and the tender period for further updates.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.2% of the 326 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLNO was trading at $52.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.